Attached files
| file | filename |
|---|---|
| 8-K/A - FORM 8K/A - PAR PHARMACEUTICAL COMPANIES, INC. | form8kaanchenfeb12012.htm |
| EX-99.2 - CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - PAR PHARMACEUTICAL COMPANIES, INC. | exhibit992financialstat20102.htm |
| EX-99.1 - AUDITED CONSOLIDATED FINANCIAL STATEMENTS - PAR PHARMACEUTICAL COMPANIES, INC. | ex991anchenfinancial20082010.htm |
| EX-99.3 - UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS - PAR PHARMACEUTICAL COMPANIES, INC. | exhibit993proformafeb22012.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT PUBLIC ACCOUNTING FIRM
We consent to the use in this Current Report on Form 8-K/A of Par Pharmaceutical Companies, Inc. of our report dated April 14, 2011 relating to the consolidated financial statements of Anchen Incorporated (which report expresses an unqualified opinion and includes an explanatory paragraph related to the spin-off of Anchen Taiwan) as of and for the years ended December 31, 2010 and 2009, and our report dated July 31, 2010 (April 14, 2011 as to effects of the restatement discussed in Note 2) related to the consolidated financial statements of Anchen Incorporated (which report expresses an unqualified opinion and includes an explanatory paragraph related to the restatement of the 2009 and 2008 consolidated financial statements) as of and for the years ended December 31, 2009 and 2008.
/s/ Melby & Meador Accountancy Corp.
Diamond Bar, California
January 31, 2012